GLMD:NASDAQGalmed Pharmaceuticals Ltd. Analysis
Data as of 2026-10-01 - not real-time
$4.63
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
At $4.63, Galmed Pharmaceuticals Ltd. shows no decisive moving-average alignment, leaving the trend neutral. It has lost 3.6% over the past 30 days.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support.
Risk scores 5 out of 10, which is moderate for this asset class. With a beta of 0.67, position sizing matters here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 4/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support.
Risk scores 5 out of 10, which is moderate for this asset class. With a beta of 0.67, position sizing matters here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 4/10.
Top Market Events
/PRNewswire/ -- Galmed Pharmaceuticals Ltd.Galmed Pharmaceuticals Ltd. NASDAQ: GLMD "Galmed" or the "Company" , a clinical-stage biopharmaceutical company focused...The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Thin trading liquidity raises execution risk
- Beta of 0.67 versus the benchmark
- Price-to-book of 0.36
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Thin trading liquidity raises execution risk
- Price-to-book of 0.36
- Negative return on equity of -68.2%
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Negative return on equity of -68.2%
- Negative free cash flow
- Price-to-book of 0.36
Key Metrics & Analysis
Financial Health
P/E Ratio-4.5
ROE-68.21%
ROA-30.19%
Debt/Equity1.01
P/B Ratio0.4
Op. Cash Flow$-8543000
Free Cash Flow$-5274625
Technical Analysis
TrendNeutral
MACDNeutral
VolumeStable
Fear & Greed Index92.25
Valuation
GradeFair
TypeBlend
Risk Assessment
Beta0.67
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.